Kobo Biotech Ltd (KOBO) is currently trading at 4.54 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Kobo Biotech Ltd. is a key player in the pharmaceutical sector, focusing on the production of active pharmaceutical ingredients (API). The company possesses significant expertise in diketene chemistry, with manufacturing facilities in Andhra Pradesh supporting diverse applications in pigments, pharmaceuticals, and pesticides. Their biotech division in Solapur, Maharashtra, specializes in producing pharmaceutical intermediaries like pseudoephedrine, with a notable past USFDA approval for these facilities. Kobo Biotech has formed strategic international partnerships, including a technical agreement with Chinese and US firms, reinforcing its capability in technology transfer and product development. The company became a subsidiary of Arch Pharmalabs Limited in 2009, highlighting a significant ownership change and aligning with a larger pharmaceutical player.

Over the past 52 weeks, Kobo Biotech Ltd has traded between a low of ₹1.99 and a high of ₹9.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Kobo Biotech Ltd has a market capitalization of approximately 11.03. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Kobo Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -2.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 11.03 Cr, Kobo Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Kobo Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Kobo Biotech Ltd is -2.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.